The Association of MMP-9 Enzyme Activity, MMP-9 C1562T Polymorphism, and MMP-2 and -9 and TIMP-1, -2, -3 , and -4 Gene Expression in Lung Cancer
- 1 October 2009
- journal article
- research article
- Published by SAGE Publications in Genetic Testing and Molecular Biomarkers
- Vol. 13 (5) , 671-678
Abstract
Aim: To investigate the association of gene expression of MMP-2 and -9, and TIMP-1, -2, -3, and -4 and polymorphism frequencies of MMP-9 C1562T and plasma MMP-9 enzyme activity in lung cancer patients. Methods: In this study, DNA and RNA samples were extracted from peripheral blood of 300 subjects (200 lung cancer patients and 100 controls). MMP-9 C1562T polymorphism was determined using restriction fragment length polymorphism (RFLP) method, and expression of MMP-2 and -9, TIMP-1, -2, -3, and -4 was determined using reverse transcriptase polymerase chain reaction. Plasma MMP-9 enzyme activity levels were measured using enzyme-linked immunosorbent assay. Results and Conclusion: The frequencies of C1562T genotypes were found to be CC 67%, CT 30%, and TT 3% in the control group and CC 75%, CT 24%, and TT 1% in the patient group. It was determined that CC genotype frequency increases significantly in patients according to control group. Plasma MMP-9 enzyme activity levels increased in patients with lung cancer compared to the control group. The cut-off value of MMP-9 enzyme activity was determined as 7.76 ng/mL by receiver operating characteristics curve analysis. The sensitivity, specificity, positive predictive value, and negative predictive value were 77%, 51%, 75.9%, and 52.6%, respectively. The expression of MMP-2 and TIMP-1 was found to be higher in lung cancer patients. Finally, we claim that determination of MMP-9 enzyme levels and expression of MMP-2 and -9 and TIMP-1 can be used as a marker in lung cancer.Keywords
This publication has 33 references indexed in Scilit:
- Lung Cancer, Smoke Exposure, and SexJournal of Clinical Oncology, 2007
- Tissue inhibitor of metalloproteinase 1 is an independent predictor of prognosis in patients with nonsmall cell lung carcinoma who undergo resection with curative intentCancer, 2005
- Matrix Metalloproteinase Inhibitors and Cancer—Trials and TribulationsScience, 2002
- Excretion of matrix metalloproteinases 2 and 9 in urine is associated with a high stage and grade of bladder carcinomaUrology, 2001
- Metalloproteinases: role in breast carcinogenesis, invasion and metastasisBreast Cancer Research, 2000
- Role of gelatinases MMP-2 and MMP-9 in tissue remodeling following acute lung injuryBrazilian Journal of Medical and Biological Research, 2000
- Membrane associated matrix metalloproteinases in metastasisBioEssays, 1999
- The plasmin cascade and matrix metalloproteinases in non-small cell lung cancerThorax, 1999
- Matrix metalloproteinase inhibitorsBreast Cancer Research and Treatment, 1998
- Compensation as a risk factor for lung cancer in smokers who switch from nonfilter to filter cigarettes.American Journal of Public Health, 1989